Form 4 for ELUT ELUTIA INC.
Accepted 2024-08-13 00:00:00 ET · period of report 2024-08-12 · accession 0001415889-24-021194 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-13 | 2024-08-12 | ELUT | Ferguson Matthew | CFO | M - OptEx | — | +50.0K | 307.8K | +19% | — |
| D | 2024-08-13 | 2024-08-12 | ELUT | Ferguson Matthew | CFO | F - Tax | $2.84 | -17.8K | 290.0K | -6% | -$50.7K |
| D | 2024-08-13 | 2024-08-12 | ELUT | Ferguson Matthew | CFO | M - OptEx | $0.00 | -50.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-08-12 | M | A | 50,000 | — | 307,823 | D | — | — | (F1) Transaction represents shares of the Issuer's Class A Common Stock received from the vesting of restricted stock units. (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| 2 | Common | Class A Common Stock | 2024-08-12 | F | D | 17,840 | $2.84 | 289,983 | D | — | — | (F3) Shares withheld by the Issuer to satisfy tax withholding requirements on vesting of restricted stock units. |
| 3 | Derivative | Restricted Stock Units | 2024-08-12 | M | D | 50,000 | $0.00 | 0 | D | — · — to — | 50,000 Class A Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. (F4) On January 31, 2024, the Reporting Person was granted 50,000 restricted stock units. The restricted stock units vested on the 10th business day following the clearance by the U.S. Food & Drug Administration ("FDA") of the Company's CanGarooRM antibiotic-eluting biologic envelope, unless such date is not during one of the Company's open trading windows, in which case such RSUs vested as of the first business day of the next open trading window. The CanGarooRM antibiotic-eluting biologic envelope, now known as EluPro, was cleared by the FDA on June 14, 2024 and the first business day of the next open trading window was August 12, 2024. |